Earlier IPF Treatment Insights

August 10, 2026

Traditional IPF trial endpoints often miss the tissue changes happening in real time. Our Nordic IPF™ panel however provides blood-based biomarkers that assess key disease processes such as active fibrosis, which can provide early insights into treatment effects.

Watch this video with our Scientific Director of Pulmonary Research, Jannie Marie Bülow Sand, to learn how the Nordic IPF™ panel panel consisting of biomarkers such as nordicPRO-C3™ or nordicPRO-C6™ can support your clinical trials by providing earlier evidence.